---
layout: post
title: "Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma (IND.227)"
citation: "The Lancet, 2023. Tu W â€” Senior Biostatistician; randomized phase III CCTG/IFCT/NCIN trial."
---

Phase III open-label RCT comparing pembrolizumab + chemotherapy vs chemotherapy in advanced mesothelioma.
